Kong Qing-Feng, Jiao Jun-Bo, Chen Qian-Qian, Li Long, Wang Dong-Guang, Lv Bin
Department of Ultrasound, Jining NO.1 People's Hospital, No.6 Jiankang Road, Central District, Jining, 271011, Shandong, China.
Tumour Biol. 2014 Mar;35(3):2655-9. doi: 10.1007/s13277-013-1349-z. Epub 2013 Nov 7.
The aim of this study is to compare the overall survival in patients with hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) versus RFA alone. All eligible studies were collected from the PubMed, the Cochrane Library, and the Embase electronic databases. The outcomes were overall survival rates. We used odds ratios to assess the strength of the association, and 95% confidence intervals give a sense of the precision of the estimate. Statistical analyses were performed by Review Manager 5.0 and Stata 11.0. A total of 19 available studies were considered in the present meta-analysis. When all groups were pooled, meta-analysis showed that RFA plus TACE significantly improved the survival rates of patients with HCC at 1, 3, and 5 years compared with RFA alone. The combination of RFA with TACE has advantages in improving overall survival rate, and provides better prognosis for HCC patients.
本研究旨在比较接受射频消融(RFA)联合经动脉化疗栓塞术(TACE)治疗的肝细胞癌(HCC)患者与仅接受RFA治疗的患者的总生存率。所有符合条件的研究均从PubMed、Cochrane图书馆和Embase电子数据库中收集。结局指标为总生存率。我们使用比值比来评估关联强度,95%置信区间给出了估计的精确度。采用Review Manager 5.0和Stata 11.0进行统计分析。本荟萃分析共纳入19项可用研究。当所有组进行汇总时,荟萃分析表明,与单纯RFA相比,RFA联合TACE显著提高了HCC患者1年、3年和5年的生存率。RFA与TACE联合应用在提高总生存率方面具有优势,为HCC患者提供了更好的预后。